Phenothiazines Enhance the Hypothermic Preservation of Liver Grafts: A Pilot in Vitro Study

Fengwu Li¹, Zhiying Yang², Christopher Stone³, Jamie Y. Ding³, Lauren Previch³, Jiamei Shen¹,³, Yu Ji¹, Xiaokun Geng¹, and Yuchuan Ding³

Abstract
In vitro liver conservation is an issue of ongoing critical importance in graft transplantation. In this study, we investigated the possibility of augmenting the standard pre-transplant liver conservation protocol (University of Wisconsin (UW) cold solution) with the phenothiazines chlorpromazine and promethazine. Livers from male Sprague-Dawley rats were preserved either in UW solution alone, or in UW solution plus either 2.4, 3.6, or 4.8 mg chlorpromazine and promethazine (C+P, 1:1). The extent of liver injury following preservation was determined by alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, the ratio of AST/ALT, morphological changes as assessed by hematoxylin-eosin staining, apoptotic cell death as determined by ELISA, and by expression of the apoptotic regulatory proteins BAX and Bcl-2. Levels of glucose (GLU) and lactate dehydrogenase (LDH) in the preservation liquid were determined at 3, 12, and 24 h after incubation to assess glucose metabolism. Oxidative stress was assessed by levels of superoxide dismutase (SOD), reactive oxygen species (ROS), and malondialdehyde (MDA), and inflammatory cytokine expression was evaluated with Western blotting. C+P augmentation induced significant reductions in ALT and AST activities; the AST/ALT ratio; as well as in cellular swelling, vacuolar degeneration, apoptosis, and BAX expression. These changes were associated with lowered levels of GLU and LDH; decreased expression of SOD, MDA, ROS, TNF-α, and IL-1β; and increased expression of Bcl-2. We conclude that C+P augments hypothermic preservation of liver tissue by protecting hepatocytes from ischemia-induced oxidative stress and metabolic dysfunction. This result provides a basis for improvement of the current preservation strategy, and thus for the development of a more effective graft conservation method.

Keywords
graft, organ transplantation, liver conservation, hypothermic preservation, oxidative injury

Introduction
Because liver transplantation is the principal treatment for end-stage liver diseases, the temporal limitation imposed on the number of viable donor organs by the current method of liver graft preservation constitutes a major problem for patients with this disease. Liver preservation consists of the methods employed to minimize in vitro damage to tissue in advance of engraftation. For decades, this was achieved through the maintenance of low environmental temperatures (0–4°C) that function to decrease the metabolism and decelerate the degeneration of liver function¹. More recently, organ preservation solutions such as the University of Wisconsin (UW) cold storage solution have emerged to augment static cold storage (SCS)²; UW accomplishes this by reducing oxidative injury and metabolic disorder³. Despite widespread adoption of UW augmentation,
However, cell damage and loss continue to limit the duration of graft preservation possible with the current methodology.

The neuroleptic drugs chlorpromazine and promethazine (C+P), both derivatives of the drug phenothiazine, have been used for their anti-psychotic and sedative effects since the 1950s. Often administered in combination, C+P appear to exert their effects on the nervous system through the inhibition of carbohydrate oxidation; several studies have reported beneficial antioxidant effects achieved with these agents. Additionally, recent unpublished data from our group have demonstrated that phenothiazines applied after stroke suppress brain metabolism and decrease peroxide production.

The impaired metabolic state with interrupted mitochondrial activity to which liver grafts are subjected in advance of transplantation causes disrupted energy production, resulting in ischemic injury. Under these ischemic conditions, oxygen deprivation impairs oxidative metabolism, significantly limiting ATP production and leading to an overproduction of reactive oxygen species (ROS) that enhances cellular injury. Because of the depressive effect of phenothiazines on oxidative metabolism and injury, we hypothesized that addition of C+P to the UW solution would result in reductions in ROS production and liver cell damage/loss, leading to improved liver preservation. Therefore, we evaluated the effect of phenothiazine-supplemented conservation solution on the rat liver using multiple indices of liver function, measurement of morphological changes, and assessment of the associated oxidative and inflammatory mechanisms in which we expected the phenothiazines to intervene.

Materials and Methods

Subjects

A total of 48 adult male Sprague-Dawley rats (240–260 g, Vital River Laboratory Animal Technology Co., Ltd., Beijing, China) were used in this study. The experimental protocol was approved by the Animal Care and Use Committee of Capital Medical University (Beijing, China), in accordance with the National Institutes of Health (NIH, Bethesda, MD, USA) Guide for the Care and Use of Laboratory Animals. After the rats were adequately anesthetized, a laparotomy was performed through a midline incision. The distal end of the portal pedicle was ligated when a cannula was inserted and fixed with UW solution (Viaspan; DuPont Merck Pharmaceutical Company, Wilmington, DE, USA, preserved at 4°C). Often administered in combination, C+P appear to exert their effects on the nervous system through the inhibition of carbohydrate oxidation; several studies have reported beneficial antioxidant effects achieved with these agents. Additionally, recent unpublished data from our group have demonstrated that phenothiazines applied after stroke suppress brain metabolism and decrease peroxide production.

The impaired metabolic state with interrupted mitochondrial activity to which liver grafts are subjected in advance of transplantation causes disrupted energy production, resulting in ischemic injury. Under these ischemic conditions, oxygen deprivation impairs oxidative metabolism, significantly limiting ATP production and leading to an overproduction of reactive oxygen species (ROS) that enhances cellular injury. Because of the depressive effect of phenothiazines on oxidative metabolism and injury, we hypothesized that addition of C+P to the UW solution would result in reductions in ROS production and liver cell damage/loss, leading to improved liver preservation. Therefore, we evaluated the effect of phenothiazine-supplemented conservation solution on the rat liver using multiple indices of liver function, measurement of morphological changes, and assessment of the associated oxidative and inflammatory mechanisms in which we expected the phenothiazines to intervene.

Measurement of Liver Function

To evaluate hepatocyte integrity after incubation, 2 ml of preservation liquid was collected from all groups and measured with the COBAS INTEGRA 800 analyzer (COBAS, Mannheim, Germany) using the enzyme multiplied immunosay technique (EMIT) for detection of aspartate aminotransferase (AST), alanine aminotransferase (ALT), glucose (GLU), and lactate dehydrogenase (LDH). To further evaluate damage to hepatocytes, the AST/ALT ratio was calculated.

Histological Evaluation of Cell Damage

Tissue sections were cut into 4 μm-thick slices and stained with hematoxylin-eosin (H&E). The extent of hepatocyte injury was then determined under light microscopy (Carl Zeiss, Jena, Germany) by evidence of architectural alteration and vacuolization. This evidence was collected by a pathologist in a blinded manner. Four fields per section, totaling 5000 μm², were analyzed under 100x magnification using a computerized image system (Axiovision release 4.7/05-2008, Carl Zeiss) coupled to an optical microscope (Axioskop40). The ratio of dead/injured hepatocytes to the total number of hepatocytes was calculated; cell injury/death was indicated by the presence of swelling and vacuolar degeneration. To quantify the severity of hepatic injury, a point-counting method on an ordinal scale was used as follows: a grade of 0 was assigned when there was either minimal or no evidence of injury; a grade of 1 was assigned to cells demonstrating mild injury, consisting of cytoplasmic vacuolization and nuclear pyknosis; a grade of 2 was assigned to cells demonstrating moderate-to-severe injury with extensive pyknosis, cytoplasmic hypereosinophilia, and loss of intercellular borders; a grade of 3 was assigned to cells demonstrating severe necrosis with disintegration of hepatic cords, hemorrhage, and neutrophilic infiltration; and a grade of 4 was assigned to cells demonstrating very severe necrosis with disintegration of hepatic cords, hemorrhaging, and neutrophilic infiltration. In our study, a grade of anything greater than 1 on this scale was defined as hepatocyte damage.

Apoptotic Cell Death Detection by ELISA

In both the control and C+P groups, enzyme immunoassay was used to quantify apoptosis-related DNA fragmentation by detecting cytoplasmic histone-associated DNA fragments (Cell Death Detection ELISA; Roche Diagnostics, Indianapolis, IN, USA), as described previously by us.
**SOD and MDA Detection**

To quantify the extent of oxidative injury, malondialdehyde (MDA) and superoxide dismutase (SOD) concentrations were measured in homogenized liver using fluorescence detection. In accordance with the manufacturer’s instructions (Jiancheng Biotech Co., Nanjing, China), MDA content and SOD activity were monitored with a microplate reader (Thermo Scientific Multiskan MK3, Kanze Laboratory Equipment Co., Shanghai, China) at 532 and 450 nm by MDA and SOD ELISA kits, respectively.

**ROS Production**

To assess the effect of phenothiazines on oxidative injury of graft hepatocytes, levels of ROS production were determined. The method by which ROS were measured was used by our group previously, and consists in the use of hydrogen peroxidase ($H_2O_2$) linked to a fluorescent compound to detect $H_2O_2$. Because it dismutates enzymatically (or rapidly in the absence of enzyme catalysis) into $H_2O_2$, superoxide is reliably quantified by this method. First, liver tissue was homogenized in buffer (mannitol 225 mM, sucrose 75 mM, EGTA 1 mM, HEPES 5 mM pH 7.4, 1 mg/ml fatty acid-free BSA, 0.1% Triton-X-100). Then, employing the BCA method for determining protein concentration, samples were diluted to 10 mg/ml, and 100 µg/ml digitonin was added. After 30 min incubation, $H_2O_2$ in liver homogenates was detected using a commercially available kit (Jiancheng Biotech Co., Nanjing, China). $H_2O_2$ was combined with molybdic acid to form a complex, which was measured at 405 nm, and the content of $H_2O_2$ was then calculated using a microplate reader (Thermo Scientific Multiskan MK3).

**Protein Expression**

Western blot analysis was used to detect protein expression in the ischemic tissue, as described by us in previous work. Upon completion of electrophoresis, proteins were transferred to polyvinylidene fluoride membranes, which were incubated with primary antibodies (rabbit polyclonal anti-Bcl-2, rabbit polyclonal anti-BAX antibody, rabbit polyclonal anti-TN-Fz antibody, or rabbit polyclonal anti-IL-1β antibody; Abcam, Cambridge, MA, USA) for 24 h at 4°C. Next, membranes were washed with PBS three times for 6 min per wash, and then re-incubated with a secondary antibody (goat anti-rabbit IgG, Santa Cruz, Dallas, TX, USA; goat anti-mouse IgG, Abcam) for 1 h at room temperature. Finally, an enhanced chemiluminescence system was used to detect immunoreactive bands. Western blot images for each antibody, including β-actin, were analyzed using an image analysis program (Image J 1.42, NIH, Bethesda, MD, USA) to represent protein expression in terms of relative image density; mean protein expression from the control group was assigned a value of 1 to serve as a reference.

**Statistical Analysis**

Statistical analysis was performed with SPSS for Windows, version 17.0 (SPSS, Inc., Chicago, IL, USA). The differences among groups were assessed using one-way ANOVA with the significance level set at $P < 0.05$. Post-hoc comparison among groups was performed using the least significant difference (LSD) test.

**Results**

**Levels of ALT, AST, and the AST/ALT Ratio**

Preservation solutions were collected from all groups at 3, 12, and 24 h after incubation. Compared with controls, 2.4 mg phenothiazine did not yield any effect on ALT levels (165.8 vs 165.3 unit/L at 3 h, 417 vs 315 unit/L at 12 h, and 419 vs 356.5 unit/L at 24 h). In the 3.6 mg group, a significant, but relatively small, decrease was found at 3 (108.5 vs 165.3 unit/L, $P < 0.05$) and 24 h (310.5 vs 356.5 unit/L, $P < 0.05$). In the 4.8 mg group, however, ALT levels in the preservation solution were significantly and markedly decreased at all three time points: 3 (54.3 vs 165.3 unit/L, $P < 0.01$), 12 (141.8 vs 315 unit/L, $P < 0.01$), and 24 h (154.7 vs 356.5 unit/L, $P < 0.01$) after incubation, as compared with the control group (Fig 1A). Similar reductions in AST levels were observed in C+P-treated groups (Fig 1B). Furthermore, the AST/ALT ratio yielded by C+P treatment was significantly decreased in the 3.6 (1.1 vs 1.6 at 12 h, $P < 0.05$; 1.2 vs 1.7 at 24 h, $P < 0.05$) and 4.8 mg groups (1.1 vs 1.6 at 12 h, $P < 0.05$; 1.1 vs 1.7 at 24 h, $P < 0.05$) (Fig 1C). These results indicate that phenothiazines possess a dose-dependent potential to reduce liver damage during pre-engraftment storage.

**Morphological Cell Damage**

Phenothiazine treatment (4.8 mg) mitigated hepatocellular injury at all time points (3, 12, and 24 h after incubation), maintaining tissue architecture and reducing edema compared with the control group (Fig 2A). The damaged hepatocyte ratio, which was determined, as described above, by the presence of severe swelling and vacuolar degeneration, was therefore also reduced at all time points: 3 (7.8 vs 11.8, $P < 0.05$), 12 (15.1 vs 20.0, $P < 0.05$), and 24 h (23.7 vs 38.7, $P < 0.05$) (Fig 2B).

**Detection of Apoptosis and Apoptotic Protein Expression**

Compared with control groups, cell death was significantly decreased in all groups that underwent C+P incubation (2.5 vs 3.0 at 3 h, $P < 0.05$; 2.5 vs 3.1 at 12 h; 2.5 vs 3.5 at 24 h, $P < 0.01$) (Fig 3A). Additionally, Western blot was used to...
measure protein expression changes attributable to C+P. The expression of pro-apoptotic (BAX) and anti-apoptotic proteins (Bcl-2) were measured at 3, 12, and 24 h after C+P incubation. In the 4.8 mg C+P treatment group, a significant decrease (\( P < 0.05 \)) in BAX expression was seen at 3 (1.0 vs 0.6), 12 (1.4 vs 1.2), and 24 h (1.6 vs 1.3) (Fig 3B); similarly, a significant (\( P < 0.05 \)) increase in Bcl-2 expression was seen in the 4.8 mg C+P treatment group at 3 (0.6 vs 0.8) and 24 h (1.0 vs 1.2), while an increase that did not reach statistical significance was seen at 12 h (0.8 vs 1.0) (Fig 3C). These findings indicate that C+P may both inhibit pro-apoptotic protein expression, and enhance expression of anti-apoptotic proteins.

**GLU and LDH Levels**

At 2.4 mg, phenothiazine augmentation did not produce any effect on GLU levels (Fig 4A). In the 3.6 mg group, however, a significant decrease was found at 3 (0.9 vs 1.6 unit/L, \( P < 0.05 \)), 12 (2.6 vs 4.2 unit/L, \( P < 0.05 \)), and 24 h (3.0 vs 5.2 unit/L, \( P < 0.05 \)); GLU levels were also significantly decreased in the 4.8 mg group at 3 (0.9 vs 1.6 unit/L, \( P < 0.01 \)), 12 (2.5 vs 4.2 unit/L, \( P < 0.05 \)), and 24 h (3.0 vs 5.2 unit/L, \( P < 0.05 \)) after incubation. Similar results were observed for LDH (Fig 4B). These results suggest that phenothiazines exert a dose-dependent suppressive effect on brain metabolism.

**ROS, SOD and MDA Levels**

In tissue preserved in UW solution augmented with phenothiazines, ROS levels were significantly decreased at 3 (20.1 vs 33.2 mmol/g, \( P < 0.05 \)), 12 (81.5 vs 96.1 mmol/g, \( P < 0.05 \)), and 24 h (69.6 vs 102.8 mmol/g, \( P < 0.01 \)) compared with UW solution alone (Fig 5A). The activity of SOD in liver tissue treated with phenothiazines (4.8 mg), in contrast, was significantly increased at 3 (136.3 vs 128.5 unit/mg, \( P < 0.05 \)), 12 (101.9 vs 93.3 unit/mg, \( P < 0.05 \)), and 24 h (106.5 vs 84.9 unit/mg, \( P < .05 \)) (Fig 5B). MDA concentration in liver tissue treated with 4.8 mg C+P (6.2 vs 7.9 unit/mg at 3 h, \( P < 0.05 \); 4.3 vs 6.4 unit/mg at 12 h, \( P < 0.05 \); 13.6 vs 31.8 unit/mg at 24 h, \( P < 0.01 \)) was, like ROS levels, significantly reduced (Fig 5C). These results suggest that the augmentation phenothiazines provide to the protective effects of cold liver preservation occurs, at least in part, through inhibition of oxidative stress.

**Inflammatory Protein Expression**

To investigate whether an anti-inflammatory action also contributes to the augmentation exerted by phenothiazines,
we compared expression of the pro-inflammatory cytokines TNF-α and IL-1β in tissue preserved with phenothiazines plus UW solution with expression in the presence of UW solution alone. In the 4.8 mg C+P treatment group, a significant decrease ($P < 0.05$) in IL-1β expression was seen at 24 h (1.3 vs 0.8), while slight decreases were seen at 3 (0.6 vs 0.5) and 12 h (1.3 vs 1.1) (Fig 6A). Similarly, a significant ($P < 0.05$) decrease in TNF-α expression was seen in the 4.8 mg C+P treatment group at 24 h (1.3 vs 1.1), while decreases that did not reach statistical significance were seen at 3 (0.7 vs 0.6) and 12 h (0.9 vs 0.6) (Fig 6B). These findings indicate that C+P may exert an inhibitory effect on the expression of pro-inflammatory cytokines.

**Discussion**

In this study, we demonstrated that phenothiazine augmentation enhanced liver graft preservation by UW solution, as demonstrated by reductions in histologically determined tissue damage, hepatic enzyme leakage, glucose metabolism, and oxidative injury. To our knowledge, this is the first study to demonstrate these effects; it is also the first study to describe their underlying anti-inflammatory and antioxidant mechanisms.

The phenothiazines with which these effects were achieved, chlorpromazine and promethazine, have been widely used, and often in combination, for their antipsychotic and sedative effects. Chlorpromazine is a low-potency typical antipsychotic with primarily anticholinergic and anti-adrenergic side effects. Promethazine is a first-generation antihistamine clinically used for its strong sedative, antiemetic, and weak antipsychotic effects. In addition to these more widely-known effects, however, the combination of these two drugs has been demonstrated to induce a hypometabolic state that has been referred to as artificial hibernation, in the setting of which our group observed a dose-dependent neuroprotective effect following both transient and permanent ischemia. Thus, having found
In clinical liver transplantation, prolonged durations of cold ischemic preservation are associated with primary dysfunction and loss of grafts. Although the cause of this dysfunction is likely multifactorial (other potential causes include steatosis, prolonged donor warm ischemia, and poor organ flushing)\textsuperscript{27}, any achievable reduction in injury incurred during preservation should limit the risk of dysfunction, and thus make better use of available livers. Unfortunately, in the three decades following the advent of the UW organ flush solution in 1987, there has been no further...
significant progress in minimizing the incidence of hypothermic liver preservation injury. UW solution protects liver cells by decreasing energy depletion and lipid peroxidation, and allows preservation of donor livers for up to 12–18 h in clinical settings. In this study, augmentation of UW solution by phenothiazines was shown to constitute the advance in graft preservation efficacy that has been elusive in recent history. Phenothiazine augmentation reduced cell damage by suppressing oxidative stress, inflammation, and brain metabolism, as determined by measurements of cell morphology, apoptosis, BAX, Bcl-2, ROS, SOD, MDA, ALT, AST, GLU, LDH, IL-1β, and TNF-α.

The results of these measurements accord with previous research regarding the metabolic effects of phenothiazines. Previous studies have demonstrated that mitigation of ischemic injury is one of the mechanisms whereby...
phenothiazines exert their protective effect.\(^7\) Ischemic injury, through hypoxic inhibition of oxidative phosphorylation, generates an overproduction of ROS\(^3\); ROS-induced oxidative damage has been shown to contribute to graft injury.\(^32\) In the present study, elevated SOD and decreased MDA suggest that phenothiazine-induced reductions in ischemic injury exert an enhanced antioxidant effect with positive ramifications on graft quality. ROS levels are dependent on the ratio of their production to their clearance, which is regulated by various cellular antioxidant compounds, including SOD.\(^33,34\) In basic and clinical research, SOD levels are thus used as an indicator of free radical scavenging capacity.\(^35\) MDA, an indicator of lipid peroxidation, is measured for the converse purpose of demonstrating the extent of free radical-mediated cellular damage.\(^36,37\) In addition to the oxidative mechanism, ischemic hepatocellular injury has also been shown to be associated with inflammation, and in particular with elevated levels of the pro-inflammatory cytokines TNF-\(\alpha\) and IL-1\(\beta\).\(^38\) In previous work, our group has demonstrated the capacity of phenothiazines to reduce post-stroke inflammation; likewise, the reductions in TNF-\(\alpha\) and IL-1\(\beta\) observed in this study further suggest an anti-inflammatory mechanism for phenothiazine-mediated cytoprotection.

Further work conducted by our group and others suggests a role for the endoplasmic reticulum (ER) in mediating both the inflammatory and oxidative mechanisms of cellular injury observed in this study. Specifically, the protein constituents of the ER stress (ERS) signaling pathway have been found to be upregulated in traumatic brain\(^39\) and liver\(^40,41\) injury models, while expression of TNF-\(\alpha\) and ROS has been found to be decreased when ERS was inhibited.\(^42\) A growing body of evidence suggests that there is extensive cross-talk between the inflammatory response and ERS: several stimuli (lipids, cytokines, or injury) appear to activate ERS, which then further disrupts metabolic functions, causing more inflammation.\(^44\) Mechanistically, the relationship between inflammation and ERS may include the release of calcium from the ER\(^45\), activation of the transcription factor nuclear factor-\(\kappa\)B (NF-\(\kappa\)B)\(^46\), mitogen-activated protein kinase (MAPK)\(^47\), induction of the acute phase response, and the production of ROS.\(^48\) Studies have also linked ERS to the generation and accumulation of ROS, suggesting concomitant involvement with oxidative stress.\(^48,49\) Because of the importance of the inflammatory and oxidative mechanisms suggested by the results of the present study, we intend in future work to investigate whether ERS attenuation contributes to C+P-mediated augmentation of liver graft preservation.

**Conclusion**

Despite improvements made by the use of UW solution, considerable temporal limitations continue to curtail the success of liver transplantation in both basic scientific and clinical settings. It is this circumstance that foregrounds the utility of the results obtained in this study, in which we demonstrated in vitro that augmentation of UW solution with phenothiazines provided improved protection of hepatocytes against ischemia-induced oxidative stress. In order to see whether these findings can translate into improvements in clinical efficacy, further studies in vivo that assess the effects of phenothiazine supplementation on organ preservation and transplant survival in whole animals are warranted.

**Ethical Approval**

The clinical study was approved by the Institutional Animal Investigation Committee of the Capital Medical University.

**Statement of Human and Animal Rights**

All of the experimental procedures involving animals were conducted in accordance with the Institutional Animal Investigation Committee of the Capital Medical University.

**Statement of Informed Consent**

Statement of Informed Consent is not applicable for this article.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was partially supported by the National Nature Science Foundation of China (81871838 and 81802231), the China-Japan Friendship Hospital Medical Development Research Foundation Project (2013-RC-2), the Beijing Tongzhou District Financial Fund, and the Science and Technology Plan of Beijing, Tongzhou District (KJ2018CX006-02).

**References**

1. von Horn C, Hannant P, Hauet T, Leuvenink H, Paul A, Minor T; on behalf of COPE consortium partners. Cold flush after dynamic liver preservation protects against ischemic changes upon reperfusion—an experimental study. Transpl Int. 2018; https://doi.org/10.1111/tri.13354.
2. Mangus RS, Schroering JR, Hathaway TJ, Kubal CA, Fridell JA. Comparison of histidine-tryptophan-ketoglutarate and University of Wisconsin preservation solutions in pediatric liver transplantation. Pediatr Transplant. 2018;2018:e13252.
3. Rosado J, Guerrera JV. UW vs HTK for static preservation in liver transplantation: is there a “Solution Effect” on Outcomes? Transplantation. 2018;102(11):1791–1792.
4. de Boer JD, Strelneice A, Rosmalen MV, Vries E, Ysebaert D, Guba M, Braat AE, Samuel U. The effect of histidine-tryptophan-ketoglutarate solution (HTK) and University of Wisconsin solution (UW): an analysis of the Eurotransplant Registry. Transplantation. 2018;102(11):1870–1877.
5. Cote CJ, Karl HW, Notteman DA, Weinberg JA, McCloskey C. Adverse sedation events in pediatrics: analysis of medications used for sedation. Pediatrics. 2000;106(4):633–644.
6. Burn JH. The pharmacology of chlorpromazine and promethazine. Proc R Soc Med. 1954;47(8):617–621.
7. Liu S, Geng X, Forreider B, Xiao Y, Kong Q, Ding Y, Ji X. Enhanced beneficial effects of mild hypothermia by phenothiazine drugs in stroke therapy. Neurol Res. 2015;37(5):454–460.
8. Skinner A, Spector RG. The effect of chlorpromazine on 14-C-glucose metabolism in mouse liver and brain. Br J Pharmacol Chemother. 1968;33(1):129–135.
9. Geng X, Li F, Yip J, Peng C, Elmadhoun O, Shen J, Ji X, Ding Y. Neuroprotection by chlorpromazine and promethazine in severe transient and permanent ischemic stroke. Mol Neurobiol. 2017;54(10):8140–8150.
10. Dwyer DS, Lu XH, Bradley RJ. Cytotoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism. Brain Res. 2003;971(1):31–39.
11. Olinyck SA, Zatzenko DM, Khmelev’skiy LuV. [Antioxidant properties of pharmacopoeia drugs–derivatives of the phenothiazine series]. Ukr Biokhim Zh (1978). 1993;65(4):115–119.
12. Borges MB, Dos Santos CG, Yokomizo CH, Sood R, Vitovic P, Kinnunen PK, Rodrigues T, Nantes IL. Characterization of hydrophobic interaction and antioxidant properties of the phenothiazine nucleus in mitochondrial and model membranes. Free Radic Res. 2010;44(9):1054–1063.
13. Tabka D, Bejaoui M, Javellad J, Rosello-Catafau J, Achard JM, Abdennabi HB. Effects of Institut Georges Lopez-1 and Celsior preservation solutions on liver graft injury. World J Gastroenterol. 2015;21(14):4159–4168.
14. Geng X, Fu P, Ji X, Peng C, Fredrickson V, Sy C, Meng R, Ling F, Du H, Tan X, Hattieffmann M, Guthikonda M, Ding Y. Synergistic neuroprotection of normobaric oxygenation and ethanol in ischemic stroke through improved oxidative mechanism. Stroke. 2013;44(10):1418–1425.
15. Keskitalo A, Munukka E, Toivonen R, Hollmen M, Kainulainen H, Huovinen P, Jalkanen S, Pekkala S. Enterobacter cloacae administration induces hepatic damage and subcutaneous fat accumulation in high-fat diet fed mice. Plos One. 2018;13(5):e0198262.
16. Risso PS, Koike MK, Abrahao Mde S, Ferreira NC, Montero EF. The effect of N-acetylcysteine on hepatic histomorphology during hypothermic preservation. Acta Cir Bras. 2014;29(suppl 3):28–32.
17. Jimenez-Castro MB, Casillas-Ramirez A, Mendez-Braz M, Massip-Salcedo M, Gracia-Sancho J, Elias-Miro M, Rodes J, Peralta C. Adiponecint and resistin protect steatotic livers undergoing transplantation. J Hepatol. 2013;59(6):1208–1214.
18. Liu MY, Ren YP, Zhang LJ, Ding JY. Pretreatment with ginseng fruit saponins affects serotonin expression in an experimental comorbidity model of myocardial infarction and depression. Aging Dis. 2016;7(6):680–686.
19. Mao XY, Yu J, Liu ZQ, Zhou HH. Apigenin attenuates diabetes-associated cognitive decline in rats via suppressing oxidative stress and nitric oxide synthase pathway. Int J Clin Exp Med. 2015;8(9):15506–15513.
20. Shen J, Rastogi R, Guan L, Li F, Du H, Geng X, Ding Y. Omega-3 fatty acid supplement reduces activation of NADPH oxidase in intracranial atherosclerosis stenosis. Neurol Res. 2018;40(6):499–507.
21. Li X, Ren C, Li S, Han R, Gao J, Huang Q, Jin K, Luo Y, Ji X. Limb remote ischemic conditioning promotes myelination by upregulating PTEN/Akt/mTOR signaling activities after chronic cerebral hypoperfusion. Aging Dis. 2017;8(4):392–401.
22. Li F, Pedy JT, Jr, Ding JN, Peng C, Li X, Shen J, Wang S, Geng X. Exercise rehabilitation immediately following ischemic stroke exaggerates inflammatory injury. Neurol Res. 2017;39(6):530–537.
23. Li HJ, Zhang YJ, Zhou L, Han F, Wang MY, Xue MQ, Qi Z. Chlorpromazine confers neuroprotection against brain ischemia by activating BKCa channel. Eur J Pharmacol. 2014;735:38–43.
24. Bastianetto S, Daniik M, Mennecken F, Williams S, Quirion R. Prototypical antipsychotic drugs protect hippocampal neuronal cultures against cell death induced by growth medium deprivation. BMC Neurosci. 2006;7:28.
25. Lopez-Munoz F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry. 2005;17(3):113–135.
26. MacMillan V. Effects of promethazine on the energy metabolism of normoxic and hypoxic rat brain. Stroke. 1982;13(4):464–469.
27. Boteon YL, Afford SC, Mergental H. Pushing the limits: machine preservation of the liver as a tool to recondition high-risk grafts. Curr Transplant Rep. 2018;5(2):113–120.
28. Tian T, Lindell SL, Kowalski C, Mangino MJ. Moeisin functionality in hypothermic liver preservation injury. Cryobiology. 2014;69(1):34–40.
29. Quintana AB, Guibert EE, Rodriguez JV. Effect of cold preservation/reperfusion on glycogen content of liver. Concise review. Ann Hepatol. 2005;4(1):25–31.
30. van der Plaats A, t Hart NA, Verkerke GJ, Leuvenink HG, Ploeg RJ, Rakhorst G. Hypothermic machine preservation in liver transplantation revisited: concepts and criteria in the new millennium. Ann Biomed Eng. 2004;32(4):623–631.
31. Ren C, Li S, Liu K, Rajah GB, Zhang A, Han R, Liu Y, Huang Q, Li H, Ding Y, Ji X. Enhanced oxidative stress response and neuroprotection of combined limb remote ischemic conditioning and atorvastatin after transient ischemic stroke in rats. Brain Circ. 2017;3(4):204–212.
32. Shi S, Xue F. Current antioxidant treatments in organ transplantation. Oxid Med Cell Longev. 2016;2016:8678510.
33. Bloch-Damti A, Bashan N. Proposed mechanisms for the induction of insulin resistance by oxidative stress. Antioxid Redox Signal. 2005;7(11-12):1553–1567.
34. Harris ED. Regulation of antioxidant enzymes. FASEB J. 1992;6(9):2675–2683.
35. Li W, Yang S. Targeting oxidative stress for the treatment of ischemic stroke: upstream and downstream therapeutic strategies. Brain Circ. 2016;2(4):153–163.
36. Ford ES, Mokdad AH, Giles WH, Brown DW. The metabolic syndrome and antioxidant concentrations: findings from the
third national health and nutrition examination survey. Diabetes. 2003;52(9):2346–2352.

37. Bai J, Zheng S, Jiang D, Han T, Li Y, Zhang Y, Liu W, Cao Y, Hu Y. Oxidative stress contributes to abnormal glucose metabolism and insulin sensitivity in two hyperlipidemia models. Int J Clin Exp Pathol. 2015;8(10):13193–13200.

38. Lu TF, Yang TH, Zhong CP, Shen C, Lin WW, Gu GX, Xia Q, Xu N. Dual effect of hepatic macrophages on liver ischemia and reperfusion injury during liver transplantation. Immune Netw. 2018;18(3):e24.

39. Zhang T, Lu D, Yang W, Shi C, Zang J, Shen L, Mai H, Xu A. HMG-coa reductase inhibitors relieve endoplasmic reticulum stress by autophagy inhibition in rats with permanent brain ischemia. Front Neurosci. 2018;12:405.

40. Ali A, Zhang K. Endoplasmic reticulum stress response in nonalcoholic fatty liver disease. Environmental Disease. 2018;3(2):31–37.

41. Srivastava G, Singh M, Mishra A. Ursolic acid: a natural preventive aesculapian for environmental hepatic ailments. Environmental Disease. 2017;2(3):87–94.

42. Gavini CK, Bookout AL, Bonomo R, Gautron L, Lee S, Mansuy-Aubert V. Liver X receptors protect dorsal root ganglia from obesity-induced endoplasmic reticulum stress and mechanical allodynia. Cell Rep. 2018;25(2):271–277 e4.

43. Duvigneau JC, Luis A, Gorman AM, Samali A, Kaltenecker D, Moriggl R, Kozlov AV. Crosstalk between inflammatory mediators and endoplasmic reticulum stress in liver diseases. Cytokine. 2018 pii:S1043-4666(18)30406-X.

44. Hu H, Wang C, Jin Y, Meng Q, Liu Q, Liu Z, Liu K, Liu X, Sun H. Catalpol Inhibits Homocysteine-induced Oxidation and Inflammation via Inhibiting Nox4-NF-kappaB and GRP78/PERK pathways in human aorta endothelial cells. Inflammation. 2019;42(1):64–80.

45. Sarkar Bhattacharya S, Mandal C, Albiez RS, Samanta SK, Mandal C. Mahanine drives pancreatic adenocarcinoma cells into endoplasmic reticulum stress-mediated apoptosis through modulating sialylation process and Ca(2+)-signaling. Sci Rep. 2018;8(1):3911.

46. Shu Q, Fan H, Li SJ, Zhou D, Ma W, Zhao XY, Yan JQ, Wu G. Protective effects of Progranulin against focal cerebral ischemia-reperfusion injury in rats by suppressing endoplasmic reticulum stress and NF-kappaB activation in reactive astrocytes. J Cell Biochem. 2018;119(8):6584–6597.

47. Selvakumar GP, Iyer SS, Kempuraj D, Ahmed ME, Thangavel R, Dubova I, Raikwar SP, Zaheer S, Zaheer A. Molecular association of glia maturation factor with the autophagic machinery in rat dopaminergic neurons: a role for endoplasmic reticulum stress and MAPK activation. Mol Neurobiol. 2018.

48. Ochoa CD, Wu RF, Terada LS. ROS signaling and ER stress in cardiovascular disease. Mol Aspects Med. 2018;63:18–29.

49. Zhang Z, Zhang L, Zhou L, Lei Y, Zhang Y, Huang C. Redox signaling and unfolded protein response coordinate cell fate decisions under ER stress. Redox Biol. 2018.